Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
about
Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging.Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor proteinSingle amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle productionEntropic switch regulates myristate exposure in the HIV-1 matrix proteinCrystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assemblyA multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free systemAssociation of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assayFunctional characterization of the human immunodeficiency virus type 1 genome by genetic footprintingHow HIV-1 Gag assembles in cells: Putting together pieces of the puzzle.Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin.Particle size determinants in the human immunodeficiency virus type 1 Gag proteinDetection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17.Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release.Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescueRelationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding.Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly.Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation.Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.Mapping and characterization of the N-terminal I domain of human immunodeficiency virus type 1 Pr55(Gag).Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes.Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein.Virus maturation by budding.The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent mannerRedundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly.p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing proteaseEffects of Gag mutation and processing on retroviral dimeric RNA maturation.Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.Viral late domainsRNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes.Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switchHuman immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway.Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity.Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles.A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17.Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo.A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particlesDeterminants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation
P2860
Q24523051-238B84B8-C88D-43CE-BD3B-0EE8C323435CQ24645706-2EE4BB69-76C0-4FDA-AE7E-31F91BDA9DCAQ27485930-4AABC1E9-4E82-4E1B-8EAD-E34D1B01BA38Q27642873-6C9480D5-460F-458D-96CF-7B1B9874B175Q27732646-651A5105-E793-4939-A59E-C54925E124C2Q30442168-F7F41A1C-4494-49E3-B0B1-BB657E345625Q30447057-07390092-877F-451F-83BD-B8217F65A176Q31523975-6039BD3A-680A-448B-83E7-D2A230342B9AQ33358839-D9EB2551-B47B-4550-A526-1E82F8A20FF9Q33643700-CAB68589-4EB5-422F-9631-83B78AA8AF51Q33783955-8D80D680-1C53-427D-AFFB-65145729BEACQ33784101-62276B26-30BD-44E4-A320-13BB50E4896AQ33784754-60DA6B94-04DE-44C5-B9A1-F3168E1CD729Q33785351-AD3CCEF2-4829-4B91-84AC-0818AC74D96CQ33787084-59F9E767-923C-4531-8B15-98352185ED3AQ33794223-A1AA173F-BB27-48DD-ADC2-1D398847E230Q33800960-8124A3E0-E19A-40AA-A3DB-9B7E0D7B4E1BQ33803814-0129CADD-A82D-409A-A495-62C94D409D23Q33805303-2AECF095-64A4-4D49-920C-9AAC84688143Q33809347-8E9DAB40-5F93-4313-ACD2-A663B9867C4EQ33815436-2CB6803D-E2D5-4C5E-AB7C-50863DFD5C4BQ33820522-CD2C689C-EAD7-4A8C-BC41-BCA4D9B725C3Q34068037-23629D8C-5C6C-413C-9382-13C2D76D406FQ34104639-62552970-3232-4A19-9FD2-80F04DDBF6F8Q34123957-3169C681-4E60-4301-BAE7-742D3C526D56Q34288376-B97D27F4-0726-4FEE-8231-551B2CC50CDBQ34302140-C88276F1-AFB5-48E9-B33C-B43FB28AAE36Q34304675-265E57FE-0607-4059-90ED-921BB2516E49Q34338672-63727C91-2A25-4505-8409-F7354A54E658Q34359148-EBFB0348-47A1-4603-82AC-51E2B86AD31FQ34976852-57F6B151-CBF8-4E37-A7B8-16843989661FQ35691189-5B793F56-36A6-4DDE-9A29-72F365F14186Q35829873-B778D995-275D-483F-BF57-E5C0FCC5E49EQ35830898-F097825D-61FC-490D-A056-5184A575885DQ35837753-21D5E27B-7A6B-4DE5-BF14-DFC60837356BQ35842199-D1B24413-DC80-4FBA-9C3D-5E7F6360F5F3Q35848783-BCEB22DF-20A1-41AC-8860-EC6E6483D18DQ35850368-BD7D285C-A695-49C4-B7EC-913A732F75B2Q35889311-F5B78770-2D7B-421F-817B-F41748FB75F8Q35891833-BD1C5EB1-2DCC-4552-A763-0ADBD578E630
P2860
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Distinct signals in human immu ...... inding and particle formation.
@en
type
label
Distinct signals in human immu ...... inding and particle formation.
@en
prefLabel
Distinct signals in human immu ...... inding and particle formation.
@en
P2093
P1476
Distinct signals in human immu ...... inding and particle formation.
@en
P2093
P304
P356
10.1099/0022-1317-73-12-3079
P407
P478
73 ( Pt 12)
P577
1992-12-01T00:00:00Z